Kirsten van Lom

A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia

Stefan Gröschel, Mathijs A. Sanders, Remco M. Hoogenboezem et al. · Cell · 2014 · 715 citations · Full text

Medicine, Genetics, Molecular Genetics +12

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

Flavio Forrer, Eric P. Krenning, P.P.M. Kooij et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2009 · 207 citations · Full text

Medicine, Nuclear Medicine, Radiology +17

Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Hendrik Bergsma, Kirsten van Lom, Marc H.G.P. Raaijmakers et al. · Journal of Nuclear Medicine · 2017 · 135 citations

Medicine, Hematology, Oncology +17

miRNA analysis in B‐cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR‐150 and high <i>BIC</i> /miR‐155 expression

Mindy Wang, MK Dijkstra, Kirsten van Lom et al. · The Journal of Pathology · 2008 · 113 citations

Medicine, Hematology, Oncology +15

Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study

Panagiotis Baliakas, Anastasia Hadzidimitriou, Lesley-Ann Sutton et al. · The Lancet Haematology · 2014 · 112 citations

Life Sciences, Hematology, Immunology +17